Peptide News Digest

Amylyx $500.2M Offering Closes Friday, Vivani Semaglutide Implant Advances, Chinese GLP-1 Depth, Regeneron Pasatru FOP Approval

Amylyx $500.2M closes Friday. Vivani NPM-139 semaglutide implant +20% at 1 year. Chinese Minwei-Innovent GLP-1 progress. Regeneron Pasatru FOP.

4 stories · Covering industry, clinical-trials, regulatory

Editor's Note

Friday closes the LUCIDITY-aftermath capital-markets arc for Amylyx Pharmaceuticals (NASDAQ: AMLX): the upsized $500.2 million underwritten public offering priced Wednesday at $35.50 per share for 14,090,000 shares closed as scheduled Friday August 21, 2026 with Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital as joint book-running managers. Beyond Amylyx, Vivani Medical (NASDAQ: VANI) continues to progress its long-acting NanoPortal peptide-implant program: LIBERATE-1 Phase 1 first-in-human study of NPM-115 (exenatide implant) completed with a positive safety and tolerability profile, and NPM-139 (a novel semaglutide implant) has shown greater than 20% sham-adjusted weight loss for a full year from a single implant administration in an ongoing preclinical study. Phase 1 clinical initiation for NPM-139 is targeted for H1 2026 pending regulatory clearance. Chinese biotech GLP-1 pipeline activity added depth this week with Minwei Bio's MWN105 Phase Ib clinical trial registration (CTR20253330, targeting semaglutide-intolerant populations) and Phase II registration (CTR20253336, targeting non-diabetic overweight and obese patients), plus Innovent Biologics IBI3032 FDA IND clearance August 5 and Chinese CTR re-registration August 22 (CTR20253396) as synchronized dual-region development activity. And Regeneron Pharmaceuticals (NASDAQ: REGN) received FDA approval Thursday August 20 for Pasatru (garetosmab-grts) to reduce formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP), a rare-disease approval that extends Regeneron's growing rare-disease commercial portfolio.

Amylyx Pharmaceuticals (NASDAQ: AMLX) Closed Its Upsized $500.2 Million Underwritten Public Offering as Scheduled Friday August 21, 2026, With 14,090,000 Shares of Common Stock Priced Wednesday August 19 at $35.50 per Share, Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital as Joint Book-Running Managers; The Offering Follows the Monday August 18 Phase 3 LUCIDITY Primary Endpoint Hit for Avexitide (Exendin 9-39, First-in-Class GLP-1 Receptor Antagonist Peptide) That Documented a 55% Reduction in the Composite Rate of Level 2 and Level 3 Hypoglycemic Events (P=0.000003) in Post-Bariatric Hypoglycemia; Use of Proceeds: Avexitide Commercial Launch Preparation, End-2026 NDA Submission Activities, AMX0318 (Long-Acting Follow-On) IND-Enabling Studies, and General Corporate Purposes; Underwriter 30-Day Option for Additional 2,113,500 Shares Would Bring Total Raise Capacity to Roughly $575 Million if Fully Exercised

Amylyx Pharmaceuticals (NASDAQ: AMLX) closed its upsized $500.2 million underwritten public offering as scheduled Friday August 21, 2026. Deal terms: 14,090,000 shares of common stock priced Wednesday August 19 at $35.50 per share, with Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital as joint book-running managers. The offering follows the Monday August 18 Phase 3 LUCIDITY primary endpoint hit for avexitide (exendin 9-39, first-in-class GLP-1 receptor antagonist peptide) that documented a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events (p=0.000003) in post-bariatric hypoglycemia. Use of proceeds: avexitide commercial launch preparation (Q4 2026 NDA submission), broader pipeline advancement including AMX0318 (long-acting follow-on candidate identified with Gubra A/S, IND targeted 2027), and general corporate purposes. Underwriter 30-day option for additional 2,113,500 shares at the same price less underwriting discounts and commissions would bring total raise capacity to roughly $575 million if fully exercised. Amylyx also expanded its board of directors as part of the LUCIDITY-week capital markets round. The $500 million raise provides several years of operational runway to fund the avexitide launch trajectory and the second-generation AMX0318 development program targeting the same GLP-1 receptor antagonist mechanism at a longer-acting dosing format.

Vivani Medical (NASDAQ: VANI) Continues to Progress Its Long-Acting NanoPortal Peptide-Implant Program With Two Assets in Active Development: LIBERATE-1 First-in-Human Phase 1 Clinical Study of NPM-115 (Exenatide Implant Using NanoPortal Technology) Completed With a Positive Safety and Tolerability Profile and Encouraging Performance Data; NPM-139 (Novel Semaglutide Implant) Has Demonstrated Greater Than 20% Sham-Adjusted Weight Loss for a Full Year From a Single Implant Administration in an Ongoing Preclinical Study, With Sustained Semaglutide Exposures Documented Over 231+ Days; Phase 1 Clinical Study Initiation for NPM-139 Is Targeted for H1 2026 Pending Regulatory Clearance, With Phase 2 Design Anticipated as a Randomized, Placebo-Controlled, Dose-Ranging Investigation Over 4 to 6 Months

Vivani Medical (NASDAQ: VANI) continues to progress its long-acting NanoPortal peptide-implant program with two assets in active development. NPM-115 (exenatide implant using NanoPortal technology): LIBERATE-1 first-in-human Phase 1 clinical study completed with a positive safety and tolerability profile plus encouraging performance data on exenatide release from the implant. NPM-139 (novel semaglutide implant): ongoing preclinical study has documented greater than 20% sham-adjusted weight loss for a full year from a single implant administration, with sustained semaglutide exposures documented over 231+ days. Recent preclinical readouts showed sustained semaglutide exposures and greater than 20% sham-adjusted weight loss with a single implant. Phase 1 clinical study initiation for NPM-139 is targeted for H1 2026 pending regulatory clearance. Phase 2 study design is anticipated as a randomized, placebo-controlled, dose-ranging investigation over 4 to 6 months to evaluate weight management in overweight or obese subjects. The long-acting implant delivery format addresses a substantial adherence-and-convenience gap in the current GLP-1 obesity drug class: weekly self-injection adherence in real-world claims data shows 30+ day dose gaps in a substantial share of patients within 12 months, and once-yearly implant dosing would materially change the adherence trajectory. Vivani's NanoPortal platform uses a micron-scale drug reservoir to release peptide payload at zero-order kinetics over extended durations. The category is early-stage but attracts increasing attention as GLP-1 franchise economics push toward longer-acting formats.

Chinese Biotech GLP-1 Pipeline Activity Added Depth Across the Week With Minwei Bio's MWN105 Phase Ib Clinical Trial Registration (CTR20253330, Targeting Semaglutide-Intolerant Populations) and Phase II Registration (CTR20253336, Covering Non-Diabetic Overweight and Obese Patients With BMI ≥30 or BMI 27-30 With Comorbidities) on August 19-20, Plus Innovent Biologics IBI3032 FDA IND Clearance August 5 and Chinese CTR Re-Registration August 22 (CTR20253396) as Synchronized Dual-Region Clinical Development Activity Across China and the US Extending the Growing Chinese Biotech GLP-1 Pipeline That Already Includes Hengrui-Kailera's Ribupatide (Global Phase 3 H1 2027), Innovent's Mazdutide, and Multiple Other Programs Positioning to Compete With Novo Nordisk and Eli Lilly in Global Obesity Markets

Chinese biotech GLP-1 pipeline activity added depth across the week. Minwei Bio's MWN105 registered two clinical trials on August 19-20, 2026: Phase Ib (CTR20253330) targeting semaglutide-intolerant populations (patients unable to reach target Wegovy or Ozempic doses due to GI side effects, roughly 5-10% of real-world users), and Phase II (CTR20253336) covering non-diabetic overweight and obese patients (BMI ≥30 or BMI 27-30 with weight-related comorbidities). Innovent Biologics IBI3032 received FDA IND clearance August 5, 2026 for a US Phase 1 study, and on August 22 a Chinese CTR registration (CTR20253396) was activated for synchronized dual-region development. The Chinese biotech GLP-1 pipeline continues to expand across multiple programs including Hengrui-Kailera's ribupatide (once-weekly injectable GLP-1/GIP/glucagon triple agonist, global Phase 3 planned H1 2027), Innovent's mazdutide (GLP-1/glucagon dual agonist in late-stage Chinese and US trials), and multiple novel candidates targeting differentiated patient populations. The semaglutide-intolerant population is a real gap in the current commercial landscape: patients who cannot tolerate GI side effects at 1.7 mg or 2.4 mg semaglutide often plateau at sub-therapeutic doses. A drug specifically designed for that population would address an under-served segment. The dual-region synchronized development pattern (China IND filings + US CTR / FDA IND filings in parallel) reflects Chinese biotechs' increasing sophistication at multi-market clinical strategy.

Regeneron Pharmaceuticals (NASDAQ: REGN) Received FDA Approval Thursday August 20, 2026 for Pasatru (Garetosmab-Grts, an Anti-Activin A Monoclonal Antibody Administered as Subcutaneous Injection) for the Reduction of the Formation of New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-Ups in Adults With Fibrodysplasia Ossificans Progressiva (FOP), a Rare Genetic Disease in Which Skeletal Muscle and Connective Tissue Progressively Turn Into Bone Through Extra-Skeletal Ossification Triggered by Activin A Signaling; The Pasatru Approval Marks the Second FDA-Approved Therapy for FOP After Ipsen's Sohonos (Palovarotene) Approved in 2023, Extends Regeneron's Growing Rare-Disease Commercial Portfolio Alongside Eylea (Aflibercept), Dupixent (Dupilumab), and the Antibody-Drug Conjugate Programs in Development

Regeneron Pharmaceuticals (NASDAQ: REGN) received FDA approval Thursday August 20, 2026 for Pasatru (garetosmab-grts, an anti-activin A monoclonal antibody administered as subcutaneous injection) for the reduction of the formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). FOP is a rare autosomal-dominant genetic disease affecting roughly 1 in 2 million people globally (approximately 800 patients in the US) in which skeletal muscle and connective tissue progressively turn into bone through extra-skeletal ossification triggered by activin A signaling through mutated ACVR1 (activin receptor A type 1) receptors. Patients typically develop the first flare-ups in early childhood, with progressive immobilization by adulthood as ossification advances across major joints. Pasatru's mechanism: garetosmab binds activin A and blocks its signaling through the mutated ACVR1 receptors, reducing the flare-up frequency and slowing new HO lesion formation. The approval marks the second FDA-approved therapy for FOP after Ipsen's Sohonos (palovarotene, a retinoic acid receptor gamma agonist small molecule) approved in 2023. Pasatru offers a mechanistically distinct alternative for patients who cannot tolerate palovarotene or who need combination or sequential therapy. The Pasatru approval extends Regeneron's growing rare-disease commercial portfolio alongside Eylea (aflibercept for wet AMD), Dupixent (dupilumab for atopic dermatitis and asthma), and multiple antibody-drug conjugate programs in development. Pricing and launch details have not been publicly disclosed but rare-disease pricing typically runs $300,000-$500,000 per patient per year.